About Spero Therapeutics
Spero Therapeutics is a company based in Cambridge (United States) founded in 2013 by Milind Deshpande. Spero Therapeutics has raised $114.7 million across 13 funding rounds from investors including Pfizer, HHS and RA Capital. The company has 32 employees. Spero Therapeutics offers products and services including Tebipenem HBr and SPR720. Spero Therapeutics operates in a competitive market with competitors including Nabriva, Melinta Therapeutics, Iterum Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others.
- Headquarter Cambridge, United States
- Employees 32
- Founders Milind Deshpande
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website sperotherapeutics.com
- Social LinkedIn X
- Legal Name Spero Therapeutics, Inc.
- Annual Revenue$59.62 M (USD)117.62as on Dec 31, 2025
- Net Profit$8.57 M (USD)0as on Dec 31, 2025
- EBITDA-$24 K (USD)99.97as on Dec 31, 2025
- Total Equity Funding$114.7M (USD)
in 13 rounds
- Latest Funding Round$9M (USD), Post-IPO
Nov 2022
- InvestorsPfizer
& 14 more
- Employee Count32
Products & Services of Spero Therapeutics
Spero Therapeutics offers a comprehensive portfolio of products and services, including Tebipenem HBr and SPR720.
Investigational oral carbapenem for urinary tract infections treatment.
Potential treatment for multidrug-resistant bacterial infections.
Funding Insights of Spero Therapeutics
Spero Therapeutics has successfully raised a total of $114.7M across 13 strategic funding rounds. The most recent funding activity was a Post-IPO round of $9 million completed in November 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $114.7M
- Total Rounds 13
- Last Round Post-IPO — $9M
- Investors Count 15
Latest 10 of 13 funding rounds of Spero Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2022 | $9M | Post-IPO | – | – | – |
| Jan 2022 | – | Grant | – | – | |
| Jun 2021 | $40M | Post-IPO | – | – | |
| Jul 2019 | $5M | Post-IPO | – | – | |
| Jul 2019 | $5.88M | Grant | – | – | |
| Jul 2018 | $15.7M | Grant | – | – | – |
| Mar 2017 | $6.8M | Grant | – | – | |
| Mar 2017 | $51.7M | Series C | – | Google Ventures | |
| Mar 2017 | $989,738 | Grant | – | – | |
| Feb 2016 | $30M | Series B | – | Atlas Venture, SR One | – |
15 investors in total: 15 institutional.
Investors in Spero Therapeutics
Spero Therapeutics has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Pfizer, HHS and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on solutions targeting resistant micro-organisms | – | repair-impact-fund.com | Hellerup, Denmark | |
Corporate backed venture capital fund investing in multiple sectors | – | gv.com | Mountain View, United States | |
Early-stage and late-stage biotech and finance companies are funded. | – | rockspringscapital.com | Baltimore, United States | |
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
Life science companies are funded through venture capital investments. | – | lundbeckfonden.com | Copenhagen, Denmark | |
Investments and family assets are managed by The Kraft Group. | – | thekraftgroup.com | Foxborough, United States | |
Seed and early-stage therapeutics companies are invested in by MRLV. | – | mrlv.com | Cambridge, United States | |
Early- to growth-stage startups are targeted for venture capital investments. | – | oup.vc | Bala Cynwyd, United States | |
BARDA is focused on developing medical countermeasures for public health security. | – | medicalcountermeasures.gov | United States |
Investor details for Spero Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Spero Therapeutics
38 people are tracked at Spero Therapeutics (28 in leadership, 4 in board & advisors, 6 in team); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
Milind Deshpande | Co-Founder | Leadership |
Angela Talley | Senior Vice President, Clinical Development | Leadership |
Nivedita Bhatt | Senior Director | Leadership |
Tregoning Prior | Director | Leadership |
Ian Critchley | Vice President, Head Of Clinical Microbiology | Leadership |
Hugo Lemessurier | Director | Leadership |
Sath Shukla | President & CEO | Leadership |
Myriah Satterfield | Director, Clinical Data Management | Leadership |
Frank E. Thomas | Director | Leadership |
Katie McClure (Keane) | Associate Director, FP&A | Leadership |
John Raymond | Senior Vice President Finance And Business Operations | Leadership |
Akash Jain | Vice President, Alliance Management And Business Development | Leadership |
Sarah Pileeki Wiley | Associate Director Quality Control | Leadership |
Sarah Grayson Moore | Associate Director, Clinical Operations | Leadership |
Thomas Parr | Chief Scientific Officer | Leadership |
Timothy Keutzer | Chief Operating Officer, Spero Therapeutics | Leadership |
Scott Jackson | Director | Leadership |
Ed Sopp | Vice President / Head Of Quality Assurance At Spero Therapeutics | Leadership |
Shekman Wong | Executive Director, Head Of Clinical Pharmacology, DMPK And Drug Analysis | Leadership |
Esther Rajavelu | CFO & Chief Business Officer | Leadership |
18 more people are available in the full profile.
Complete people profiles for Spero Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Spero Therapeutics
Spero Therapeutics is a publicly listed company on the NASDAQ with ticker symbol SPRO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date02 Nov 2017
- Listed onNASDAQ: SPRO
- Listed entitySpero Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS84833T1034
- Share price$1.20 (+5.26% on the day) · 2026-10-09
- Market capitalisation$69.9M
- Price to earnings11.0
- EPS (diluted, trailing year)$0.11
- Volume (last session)439,175
Financials of Spero Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $59.6M | $8.6M | -$24,000 |
| 2024 | $27.4M | -$68.6M | -$93.1M |
| 2023 | $96.7M | $22.8M | $20.1M |
| 2022 | $48.6M | -$46.4M | -$34.0M |
| 2021 | $3.1M | -$89.8M | -$102.0M |
Detailed financial statements for Spero Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Spero Therapeutics
4 dated milestones of Spero Therapeutics across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Spero Therapeutics is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $9.0M.
Competitors of Spero Therapeutics
Spero Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nabriva, Melinta Therapeutics, Iterum Therapeutics, Adaptive Phage Therapeutics and Paratek Pharma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| nabriva.com | 2006 | Vienna, Austria | $193.08M | – | Pleuromutilin antibiotics are developed for MDR infections. | |
| melinta.com | 2000 | Morristown, United States | $186M | 290 | Developer of bacterial ribosome-targeting drugs for MDR infections | |
| iterumtx.com | 2015 | Dublin, Ireland | $78.1M | – | Developer of antibiotics for MDR infections | |
| aphage.com | 2016 | Bethesda, United States | $107.87M | 78 | Therapies for multi-drug resistant infections are developed using bacteriophages. | |
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| locus-bio.com | 2015 | Raleigh, United States | $67.33M | 74 | Developer of therapeutics for infectious disease and inflammatory indications | |
| vedantabio.com | 2010 | Cambridge, United States | $350.49M | 71 | Therapeutics for infectious and autoimmune diseases are developed. | |
| allecra.com | 2013 | – | $44.44M | – | Antibiotics for multi-drug-resistant bacterial infections are developed. | |
| cubist.com | 1993 | Lexington, United States | – | 895 | Pharmaceuticals for acute care bacterial infections are developed and commercialized. |
Detailed competitors of Spero Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Spero Therapeutics
The website of Spero Therapeutics (sperotherapeutics.com) receives about 2.3K visits a month and ranks #4,462,927 among all websites worldwide, #5,401 in Biotechnology and Pharmaceuticals.
- Monthly visits2.3K
▼ 33.7% vs previous month
- Unique visitors1.5K
per month
- Global rank#4,462,927
among all websites
- Category rank#5,401
Health · Biotechnology and Pharmaceuticals
- Bounce rate38%
- Pages per visit2.2
- Average visit42 sec
- DevicesDesktop 38% · Mobile 62%
Websites whose visitors overlap most with Spero Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| voyagertherapeutics.com | 100% | 8.8K | #2,249,869 | View details |
Latest news on Spero Therapeutics
Complete news archive for Spero Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Spero Therapeutics
10 companies that operate in the same segment as Spero Therapeutics (Genitourinary Disorders), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | – | – | |
Provider of surgical devices for vertical hernia repair and abdominal wall reconstruction | 2012 | Malvern, Pennsylvania, United States | USD 104.6 M | USD 80.28 M | 209 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Miniaturized injectable neuromodulation devices are developed for chronic diseases. | 2014 | Santa Clara, California, United States | USD 123.59 M | – | – | |
Developer of a therapeutic solution to treat prostate, kidney, and bladder cancer | 2018 | Maple Grove, Minnesota, United States | USD 157 M | – | 29 | |
A device is developed to treat urinary obstruction from BPH. | 2014 | Palo Alto, California, United States | USD 48 M | – | 25 | |
Minimally invasive devices in urology | 2004 | Mountain View, California, United States | USD 137.96 M | – | 119 | |
Diagnostic devices for lower urinary tract diseases are developed. | 2021 | Aliso Viejo, California, United States | USD 94.99 M | – | 23 | |
Medical device for benign prostatic hyperplasia treatment is developed. | 2021 | Milwaukee, Wisconsin, United States | USD 54.16 M | – | – | |
Bioelectrical therapies for peripheral nervous system disorders are developed. | 2021 | London, England, United Kingdom | USD 116.07 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Spero Therapeutics
Spero Therapeutics was founded in 2013.
Spero Therapeutics is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Spero Therapeutics is a funded company, having raised a total of $114.7M across 13 funding rounds to date. The company's 1st funding round was a Series B of $30M, raised on Apr 2013.
Spero Therapeutics has 32 employees.
Annual revenue of Spero Therapeutics is $59.62M as on Dec 31, 2025.
Developer of therapeutics for drug-resistant bacterial infections. It offers a portfolio of novel product candidates which includes Tebipenem HBr, an oral carbapenem for pediatric infections, SPR720, an oral antimicrobial agent for the treatment of non-tuberculous mycobacterial lung disease, and SPR206, an intravenous (IV)-administered next-generation polymyxin analog for gram-negative bacterial infections.
Spero Therapeutics's top competitors include Melinta Therapeutics, Vedanta Biosciences and Cubist Pharmaceuticals.
Spero Therapeutics offers Tebipenem HBr and SPR720.
Yes, Spero Therapeutics is publicly traded on NASDAQ under the ticker symbol SPRO.
Spero Therapeutics has 15 investors. Key investors include Pfizer, HHS, RA Capital, CARB-X, and Atlas Venture.